Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2018-99-117485

Published: 2018

Journal Articles

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

Pierre-Edouard Debureaux, Delphine Le Febvre de Nailly, Emmanuelle Tavernier, MD, Manel Bedoui, MD, Frederique Kuhnowski, MD, Jerome Tamburini, MD PhD, Luc Mathieu Fornecker, Herve Tilly, MD, David Sibon, MD PhD, Marie-Pierre Moles, Sylvie Glaisner, MD, Jean Philippe Richardet, MD PhD, Sebastien Mule, MD PhD, Julien Calderaro, MD, Corinne Haioun, MD, Jehan Dupuis, MD

Blood (2018) 132 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2018-99-110728

Published: 2018

Journal Articles

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Blood (2016) 128 (6): 774–782.

https://doi.org/10.1182/blood-2016-02-700153

Published: 2016

Includes: Supplemental data

Journal Articles

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Blood (2016) 127 (21): 2569–2574.

https://doi.org/10.1182/blood-2016-01-693580

Published: 2016

Journal Articles

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Blood (2015) 126 (23): 393.

https://doi.org/10.1182/blood.V126.23.393.393

Published: 2015

Journal Articles

Ferric Carboxymaltose Alone or Combined with Erythropoietin Allows a Modest Increase in Hemoglobin for the Treatment of Cancer-Related Anemia in Advanced Cancer Patients

Cécile Blanc, Marie-Eglantine Dujaric, Caroline Giard, PharmD, Bernard Asselain, MD PhD, Isabelle Ferry, PharmD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD, Jacques Vargaftig, MD

Blood (2014) 124 (21): 4884.

https://doi.org/10.1182/blood.V124.21.4884.4884

Published: 2014

Journal Articles

IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Ludovic Nguyen, MD, Myrto Costopoulos, PharmD, Marie-Laure Tanguy, PharmD, Caroline Houillier, MD, Sylvain Choquet, MD, Hind Bennani, PharmD, Rwaida Elias, MD, Marine Armand, PharmD, Khe Hoang-Xuan, MD PhD, Sylvie Glaisner, MD, Sandra Malak, MD, Jacques Vargaftig, MD, Geraldine Faivre, MD, Frederic Davi, MD PhD, Helene Merle Beral, MD PhD, Magali Le Garff-Tavernier, PharmD, PhD, Carole Soussain, MD PhD

Blood (2014) 124 (21): 1619.

https://doi.org/10.1182/blood.V124.21.1619.1619

Published: 2014

NARROW

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Ferric Carboxymaltose Alone or Combined with Erythropoietin Allows a Modest Increase in Hemoglobin for the Treatment of Cancer-Related Anemia in Advanced Cancer Patients

IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only